BioVentrix to Exhibit Revivent™ System, which Surpasses Survival Benefit Threshold for Heart Failure Treatment, at European Heart Failure Congress

Published: May 22, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LISBON, Portugal--(BUSINESS WIRE)--BioVentrix, pioneer of the Less Invasive Ventricular Enhancement™ (LIVE™) procedure for the treatment of heart failure (HF), announced today that it will showcase its Revivent™ Myocardial Anchoring System at the European Heart Failure Congress (HFC) 2013, May 25-27 in Lisbon, Portugal. In clinical studies, the Revivent technology has demonstrated the ability to exceed a recently defined threshold for improving survival in HF patients. Data from a recent subgroup analysis of the National Institute of Health (NIH)-sponsored Surgical Treatment for Ischemic Heart Failure (STICH) study concluded that reducing the volume of the left ventricle (LV) to less than 60mL/m2 provided a statistically significant improvement in survival for patients suffering from HF1.

Help employers find you! Check out all the jobs and post your resume.

Back to news